[1] ARTIS D, SPITS H. The biology of innate lymphoid cells[J].Nature, 2015, 517 (7534) :293-301.
|
[2] IGNACIO A, BREDA CNS, CAMARA NOS. Innate lymphoid cells in tissue homeostasis and diseases[J]. World J Hepatol, 2017, 9 (23) :979-989.
|
[3] FORT MM, CHEUNG J, YEN D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo[J]. Immunity, 2001, 15 (6) :985-995.
|
[4] FALLON PG, BALLANTYNE SJ, MANGAN NE, et al. Identification of an interleukin (IL) -25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion[J]. J Exp Med, 2006, 203 (4) :1105-1116.
|
[5] MORO K, YAMADA T, TANABE M, et al. Innate production of T (H) 2 cytokines by adipose tissue-associated c-Kit (+) Sca-1 (+) lymphoid cells[J]. Nature, 2010, 463 (7280) :540-544.
|
[6] PRICE AE, LIANG HE, SULLIVAN BM, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity[J].Proc Natl Acad Sci U S A, 2010, 107 (25) :11489-11494.
|
[7] SAENZ SA, SIRACUSA MC, PERRIGOUE JG, et al. IL25 elicits a multipotent progenitor cell population that promotes T (H) 2 cytokine responses[J]. Nature, 2010, 464 (7293) :1362-1366.
|
[8] NEILL DR, WONG SH, BELLOSI A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity[J]. Nature, 2010, 464 (7293) :1367-1370.
|
[9] SPITS H, ARTIS D, COLONNA M, et al. Innate lymphoid cells—a proposal for uniform nomenclature[J]. Nat Rev Immuno, 2013, 13 (2) :145-149.
|
[10] CONSTANTINIDES MG, McDONALD BD, VERHOEF PA, et al. A committed precursor to innate lymphoid cells[J]. Nature, 2014, 508 (7496) :397-401.
|
[11] SEILLET C, RANKIN LC, GROOM JR, et al. Nfil3 is required for the development of all innate lymphoid cell subsets[J]. J Exp Med, 2014, 211 (9) :1733-1740.
|
[12] CHERRIER M, SAWA S, EBERL G. Notch, Id2, and RORγt sequentially orchestrate the fetal development of lymphoid tissue inducer cells[J]. J Exp Med, 2012, 209 (4) :729-740.
|
[13] HOYLER T, KLOSE CS, SOUABNI A, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells[J]. Immunity, 2012, 37 (4) :634-648.
|
[14] KLEIN WOLTERINK RG, SERAFINI N, van NIMWEGEN M, et al. Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+and IL-13+type 2 innate lymphoid cells[J]. Proc Natl Acad Sci U S A, 2013, 110 (25) :10240-10245.
|
[15] HALIM TY, MACLAREN A, ROMANISH MT, et al. Retinoicacid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation[J]. Immunity, 2012, 37 (3) :463-474.
|
[16] SPOONER CJ, LESCH J, YAN D, et al. Specification of type2 innate lymphocytes by the transcriptional determinant Gfi1[J]. Nat Immunol, 2013, 14 (12) :1229-1236.
|
[17] YANG Q, MONTICELLI LA, SAENZ SA, et al. T cell factor 1 is required for group 2 innate lymphoid cell generation[J]. Immunity, 2013, 38 (4) :694-704.
|
[18] KIM HY, UMETSU DT, DEKRUYFF RH. Innate lymphoid cells in asthma:Will they take your breath away[J]. Eur J Immunol, 2016, 46 (4) :795-806.
|
[19] SUGITA K, STEER CA, MARTINEZ-GONZALEZ I, et al. Type 2innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients[J]. J Allergy Clin Immunol, 2018, 141 (1) :300-310. e11.
|
[20] SALIMI M, BARLOW JL, SAUNDERS SP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis[J]. J Exp Med, 2013, 210 (13) :2939-2950.
|
[21] MONTICELLI LA, SONNENBERG GF, ABT MC, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus[J]. Nat Immunol, 2011, 12 (11) :1045-1054.
|
[22] LI J, RAZUMILAVA N, GORES GJ, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation[J]. J Clin Invest, 2014, 124 (7) :3241-3251.
|
[23] von MJ, JI M, LIANG HE, et al. Tuft-cell-derived IL-25regulates an intestinal ILC2-epithelial response circuit[J].Nature, 2016, 529 (7585) :221-225.
|
[24] LEE MW, ODEGAARD JI, MUKUNDAN L, et al. Activated type 2innate lymphoid cells regulate beige fat biogenesis[J]. Cel, 2015, 160 (1-2) :74-87.
|
[25] DALMAS E, LEHMANN FM, DROR E, et al. Interleukin-33-activated islet-resident innate lymphoid cells promote insulin secretion through myeloid cell retinoic acid production[J]. Immunity, 2017, 47 (5) :928-942. e7.
|
[26] LU P, JI X, WAN J, et al. Activity of group 2 innate lymphoid cells is associated with chronic inflammation and dysregulated metabolic homoeostasis in type 2 diabetic nephropathy[J].Scand J Immunol, 2018, 87 (2) :99-107.
|
[27] OLIPHANT CJ, HWANG YY, WALKER JA, et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4 (+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion[J]. Immunity, 2014, 41 (2) :283-295.
|
[28] MIRCHANDANI AS, BESNARD AG, YIP E, et al. Type 2 innate lymphoid cells drive CD4+Th2 cell responses[J]. J Immunol, 2014, 192 (5) :2442-2448.
|
[29] PENG MJ, YANG XF, WEI X, et al. Influence of hepatitis B virus infection on intrahepatic natural killer cells and innate lymphoid cell 22[J]. J Clin Hepatol, 2016, 32 (10) :1883-1887. (in Chinese) 彭梅娟, 杨晓飞, 魏欣, 等. HBV感染对肝脏自然杀伤细胞和固有淋巴样细胞22的影响[J].临床肝胆病杂志, 2016, 32 (10) :1883-1887.
|
[30] YANG Z, TANG T, WEI X, et al. Type 1 innate lymphoid cells contribute to the pathogenesis of chronic hepatitis B[J]. Innate Immun, 2015, 21 (6) :665-673.
|
[31] CAYROL C, GIRARD JP. IL-33:An alarmin cytokine with crucial roles in innate immunity, inflammation and allergy[J]. Curr Opin Immunol, 2014, 31:31-37.
|
[32] ESLAM M, GEORGE J. Genetic and epigenetic mechanisms of NASH[J]. Hepatol Int, 2016, 10 (3) :394-406.
|
[33] GAO Y, LIU Y, YANG M, et al. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis[J]. Oncotarget, 2016, 7 (23) :33649-33661.
|
[34] VASSEUR P, DION S, FILLIOL A, et al. Endogenous IL-33has no effect on the progression of fibrosis during experimental steatohepatitis[J]. Oncotarget, 2017, 8 (30) :48563-48574.
|
[35] GIESECK RL, WILSON MS, WYNN TA. Type 2 immunity in tissue repair and fibrosis[J]. Nat Rev Immunol, 2018, 18 (1) :62-76.
|
[36] McHEDLIDZE T, WALDNER M, ZOPF S, et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis[J]. Immunity, 2013, 39 (2) :357-371.
|
[37] TAN Z, LIU Q, JIANG R, et al. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells[J]. Cell Mol Immunol, 2018, 15 (4) :388-398.
|
[38] VANNELLA KM, RAMALINGAM TR, BORTHWICK LA, et al.Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2cytokine-driven inflammation and fibrosis[J]. Sci Transl Med, 2016, 8 (337) :337ra65.
|
[39] VOLAREVIC V, MITROVIC M, MILOVANOVIC M, et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis[J]. J Hepatol, 2012, 56 (1) :26-33.
|
[40] LI S, ZHU FX, ZHANG HB, et al. Pretreatment with interleukin-33 reduces warm hepatic ischemia/reperfusion injury in mice[J].Chin Med J (Engl) , 2013, 126 (10) :1855-1859.
|
[41] LIANG Y, JIE Z, HOU L, et al. IL-33 induces nuocytes and modulates liver injury in viral hepatitis[J]. J Immunol, 2013, 190 (11) :5666-5675.
|
[42] NEUMANN K, KARIMI K, MEINERS J, et al. A proinflammatory role of type 2 innate lymphoid cells in murine immune-mediated hepatitis[J]. J Immunol, 2017, 198 (1) :128-137.
|
[43] GWELA A, SIDDHANATHI P, CHAPMAN RW, et al. Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease[J]. J Crohns Colitis, 2017, 11 (9) :1124-1134.
|